| pro-SP-B | pro-SP-C |
---|
Detecting antibody | CTERMB | CFLANK | NFLANK | NFPROX | NPROSP-C-C2 |
---|
Mr of bands(kDa) | | | | | |
---|
40–42 | 7% [5] | - | - | - | - |
34–36 | 7% [5] | - | - | - | - |
25–26 | 93% [1–5,7–15] | 20% [3,5,15] | 87%+ [1–5,7–12,14,15] | - | - |
19–21 | 87%* [1–5,7–13,15] | 7% [5] | 20% [4,5,9] | 7% [4] | 7% [8] |
15 | 7% [8] | - | 7% [8] | 33%+ [2,8,9,11,12] | 7% [8] |
13 | - | - | - | 20% [3,8,9] | - |
12 | - | - | 7% [14] | - | - |
11 | - | 7% [14] | - | - | 7% [8] |
9 | - | 7% [10] | 14% [5,10] | - | - |
6 | - | - | - | - | 7% [4] |
- Percent of subjects with bands and identification numbers of those subjects in whom bands reacting with the anti-pro-SP-B-antibodies CTERMB, NFLANK, CFLANK, NFPROX and displaced by the CTERMB, NFLANK, CFLANK, NFPROX peptides, or the anti-pro-SP-C-antibody NPRO-SP-C-C2 and displaced by the respective peptide, were identified. Differences in the frequency of bands of all the disease groups were evaluated by the Fisher exact test and those with a P ≤ 0.05 were indicated by an * for comparison with the healthy control group or by a + for comparison with the disease control group, bronchitis (see table 2). The identification numbers of the patients are given in square brackets []. Numbers in bold indicate bands not identified by the CTERMB antibodies.